Compugen posts investor presentation on immuno-oncology antibody pipeline, partnerships and cash runway
CGEN•Cash runway and pipeline updates
Compugen highlighted cash balance of $125.3 million as of June 30, 2026, with expected runway into 2029.
Its ovarian cancer focus centers on COM701, an anti-PVRIG antibody, with the MAIA-ovarian interim analysis projected in Q1 2027.
Partnered programs and milestones
The pipeline update includes GS-0321, an anti-IL-18BP antibody licensed to Gilead, with a Phase 1 solid-tumor trial advancing.
The partnered program rilvegostomig, a PD-1/TIGIT bispecific derived from COM902, is in 12 Phase 3 trials under AstraZeneca.
Compugen is eligible for up to $195 million in additional rilvegostomig milestones, with tiered royalties up to mid-single digit.
